--- title: "The stock price has accumulated a rise of over 50%! Bright prospects for Giant Biogene?" type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/25065584.md" description: "Like the entire market, since September 19th, $GIANT BIOGENE(02367.HK) has experienced a significant upward trend, accumulating a rise of over 50% by November 4th, far exceeding the 同期涨幅 of the Hang Seng Index and significantly outperforming its peers in the beauty industry, such as $CHICMAX(02145.HK). Considering various factors, Giant Biogene's recent stock performance surpassing the market and its peers may be related to some positive news. Its mid-term results were impressive, and it performed exceptionally well during the Double 11 shopping festival. Giant Biogene is a leader in China's professional skincare products industry, leveraging its in-house R&D technological barriers..." datetime: "2024-11-05T02:46:36.000Z" locales: - [en](https://longbridge.com/en/topics/25065584.md) - [zh-CN](https://longbridge.com/zh-CN/topics/25065584.md) - [zh-HK](https://longbridge.com/zh-HK/topics/25065584.md) author: "[财华社](https://longbridge.com/en/profiles/11651030.md)" --- # The stock price has accumulated a rise of over 50%! Bright prospects for Giant Biogene? Like the overall market, since September 19, $GIANT BIOGENE(02367.HK) has experienced a significant upward trend, **accumulating a rise of over 50% by November 4,** far exceeding the 同期涨幅 of the Hang Seng Index and significantly outperforming peers in the cosmetics industry like $CHICMAX(02145.HK) . Considering various factors, Giant Biogene's recent stock price outperformance may be related to some positive news. #### **Strong Interim Results and Double 11 Sales Boom** Giant Biogene is a leader in China's professional skincare products industry. Through its in-house R&D technological barriers, it focuses on bioactive ingredient recombinant collagen products under its dual flagship brands, Rejuva and Kelisai, addressing various skincare needs for women of different ages and 消费能力。 Meanwhile, Giant Biogene also develops and produces functional foods based on rare ginsenoside technology. Giant Biogene disclosed its interim 业绩公告 on August 19 and officially released its 2024 interim report on September 26. The data shows that in the first half of this year, Giant Biogene achieved revenue of 2.54 billion yuan (RMB, same below), a year-on-year increase of 58.21%; **net profit attributable to the parent company was 980 million yuan, a year-on-year increase of 47.41%.** In the first half, **the Rejuva brand achieved revenue of 2.071 billion yuan, a year-on-year increase of 68.6%.** The significant revenue growth was mainly due to: 1) continuous expansion of online and offline sales channels and optimization of operational strategies, further enhancing brand influence; 2) sustained growth in revenue from star products like the Rejuva Human-like Recombinant Collagen Repair Essence; 3) continuous expansion of product categories such as 面霜， including the launch of new products like the Rejuva Recombinant Collagen Radiance Repair Cream, contributing to incremental revenue. After the release of the interim results, institutions such as China Merchants Securities (Hong Kong), TF Securities, Zheshang Securities, and Orient Securities expressed optimism. Among them, China Merchants Securities (Hong Kong) pointed out in a research report on September 26 that **Giant Biogene recorded better-than-expected interim results, and Double 11 may trigger another wave of sentiment 修复。** It is worth mentioning that China Merchants Securities (Hong Kong) also stated that, according to recent roadshows, **Giant Biogene's overall performance in the third quarter met expectations，接近 the guidance given for the second half of the year, and management expressed confidence in achieving the full-year guidance.** In terms of channels, online performance was better than offline. As the third quarter is generally a 淡季 for the cosmetics industry, the entire quarter was mainly focused on preparing for Double 11. As is well known, the 2024 Double 11 started relatively early. According to data 统计 from Li Jiaqi's Tmall live broadcast room, **Rejuva's first-day 预售 GMV for Double 11 was approximately 385 million yuan, a year-on-year increase of 126%, accounting for 74% of the entire 2023 Double 11 period, with both growth rate and 达成率 ranking first among domestic brands.** Among them, the Collagen Stick achieved sales of over 500,000 units on the first day, with a GMV of approximately 315 million yuan, making it the top 单品 among domestic brands. #### **Industry-Wide Growth Under Pressure, Leading Brands Hold Advantages** It should be noted that although Giant Biogene's interim results were impressive, and China Merchants Securities (Hong Kong) stated that its third-quarter performance met expectations, the overall cosmetics market is under pressure, with some differentiation among brands. Guotai Junan Securities released a research report on November 4 指出 that from January to September 2024，化妆品社零同比下降 1%, 4.3 percentage points lower than the overall 社零增速， **with 化妆品社零同比增长 3.4% in Q1 2024，下降 1.2% in Q2, and 下降 5.5% in Q3.** Among them, the third quarter 淡季 saw the cosmetics industry further weaken 环比 due to the 虹吸 effect of major promotions and overall 消费 pressure. Guotai Junan stated that in Q3, the cosmetics industry 格局 was relatively 分散， with significant differences in operational 节奏 among companies against the backdrop of overall weak industry demand. Looking at the performance of leading cosmetics companies listed on the A-share market in the first three quarters of 2024, only $Proya(603605.SH) and $Marubi(603983.SH) achieved both revenue and net profit growth in the first three quarters. Additionally, in the first three quarters, Yunnan Botanee Bio-Technology and Shanghai Jahwa reported "double declines" in revenue and net profit. However, Shanghai Jahwa and 贝泰妮 both reported losses in Q3, with **贝泰妮's Q3 net profit attributable to the parent company reaching a loss of 68.9993 million yuan, a year-on-year decrease of 153.41%, marking its first quarterly loss since listing.** Looking ahead for the industry, on November 3, Guolian Securities released a research report stating that Q3 saw increasingly scarce growth directions in the sector, with 加剧的企业分化， but after the 板块普涨 in September amid improved economic 修复 expectations, the valuation 中枢 of core companies has risen, with 股价上行 now more driven by EPS growth 中枢 and 确定性. Maintaining the previous investment strategy 观点，医美关注新材料 (核心是重组胶原蛋白)，新配方与新定位， **美妆把握优质国货品牌份额崛起的机遇。** Shanghai Securities also released a research report on October 28 stating that 化妆品渠道端流量分化，品牌端竞争加剧， **头部国货品牌凭借品牌 + 渠道 + 产品 + 运营等多种优势有望持续领跑。** # **Conclusion** Overall, although the cosmetics industry is under pressure, leading brands like Giant Biogene still hold advantages and have a relatively bright 前景。 It is worth noting that as leaders in the cosmetics industry, Giant Biogene and Shanghai Jahwa have been 多次入选 the "Hong Kong Top 100" list, showcasing their strong 实力。 According to the Hong Kong Top 100 official website, the 2024 Hong Kong Listed Companies Development Summit Forum and the 11th "Hong Kong Top 100" Awards Ceremony, hosted by the Hong Kong Top 100 Research Center, co-organized by 财华社 and 富途安逸， and supported by media institutions such as the Hong Kong Ta Kung Wen Wei Media Group, will be grandly held on the afternoon of November 11, 2024, at the Hong Kong Convention and Exhibition Centre. The event will 深入探讨 how to further consolidate Hong Kong's position as a global wealth management hub and capital market fundraising center, as well as how to enrich the fintech ecosystem in the new era. The Hong Kong Top 100 Research Center, based in the Greater Bay Area, has been committed to promoting financial innovation and development. Currently, the "Hong Kong Top 100" list has become one of the value benchmarks and investment 风向标 in the Hong Kong capital market. The annual event 评选出香港主板上市公司中发展良好及拥有投资价值的上市企业 through accurate data and a series of scientific evaluation criteria, releasing the list and presenting awards. The "Hong Kong Top 100" Awards Ceremony has become an important platform for 交流 in the Hong Kong capital market, witnessing the 深度融合与繁荣发展 of Hong Kong and the mainland economy, and will continue to promote the healthy development of the Hong Kong capital market and maintain Hong Kong's status as an international financial center. It remains to be seen whether Giant Biogene and Shanghai Jahwa will make the list again this year. Author: Yun Zhi Feng Qi ### Related Stocks - [02367.HK](https://longbridge.com/en/quote/02367.HK.md) - [02145.HK](https://longbridge.com/en/quote/02145.HK.md) - [603605.CN](https://longbridge.com/en/quote/603605.CN.md) - [603983.CN](https://longbridge.com/en/quote/603983.CN.md) - [YINN.US](https://longbridge.com/en/quote/YINN.US.md) - [YANG.US](https://longbridge.com/en/quote/YANG.US.md) - [00HSI.HK](https://longbridge.com/en/quote/00HSI.HK.md) - [07500.HK](https://longbridge.com/en/quote/07500.HK.md)